Epitalon dosage – how to use it and what forms are available?

Epitalon dosage is one of the most frequently discussed topics related to this peptide. This is mainly due to the lack of uniform standards and the diverse research models in which it has been analysed. In scientific literature, Epitalon doses vary depending on the species, route of administration, and study objective. In many cases, very low concentrations were used, suggesting that biological activity may occur even at minimal amounts.

W cell research effects were already observed at concentrations in the order of 10⁻¹⁷–10⁻¹⁵ M. This indicates a possible mechanism of action based on very low concentrations. In contrast, higher doses were used in in vivo studies, calculated per body weight or per individual. This clearly shows that the approach to dosing this peptide is varied.

Epitalon dosing protocol

Epitalon dosing protocols in scientific research have most commonly been based on cyclic regimens, meaning the peptide was administered for a specific period followed by a break. Animal models, such as mice and rats, doses ranged from 0.1 µg to 1 µg per individual. They were typically administered several times a week for periods ranging from several days to many months. In some long-term experiments, Epitalon was administered until the natural death of the animals, allowing its effects to be assessed with prolonged exposure.

Wbclinical trials A different approach was used. An example is the sublingual administration of 0.5 mg daily for 20 days. This shows an attempt to adapt schemes for human use. Importantly, the effects did not always increase with increasing dose. In some cases, lower concentrations produced more pronounced results than higher ones.

Epitalon injection dosage

Epitalon injection dosage is the most frequently described form of administration in the literature. In animal research Subcutaneous and intramuscular administration were used, and in some cases, intraperitoneal. Typical doses were in the microgram range. For example, 1 µg per mouse was administered five times a week for many months. In other experiments, lower doses, such as 0.1 µg per individual, were used and also resulted in noticeable biological effects.

In ophthalmological studies, Epitalon was administered topically, for example, subconjunctivally at a dose of approximately 5 µg per application for 10 days. This demonstrates the possibility of local application. The variety of these regimens indicates that the injection route was often chosen due to better control of the peptide's bioavailability and stability.

What doses Epithalon Described in research?

Published Epithalon dosages vary significantly because studies have used different species, endpoints, routes of administration, and durations of experiments. Described regimens include subcutaneous microgram-level doses in rodents, intranasal nanogram-level doses in rats, and longer, repeated regimens in ageing studies. These experimental quantities do not constitute validated human dosing recommendations. [1–7]

The most important issue is that there is no single research dosage that can be defined as the „Epitalon dose”. Different researchers have used Epithalon to answer various biological questions, and the amount administered was tailored to the specific model.

For example, in a long-term ageing study in mice, 1 μg per mouse was administered subcutaneously for five consecutive days each month, starting from the third month of life until natural death. [1] In a related study on female CBA mice, a dose of 0.1 μg per animal was used for five consecutive days each month, starting from the sixth month of life until death. [2]

Other studies used more continuous regimens. Female rats exposed to various lighting conditions received 0.1 μg per rat five times a week, starting from the fourth month of life. [3] A similar gerontological study on male rats also used 0.1 μg per rat subcutaneously five times a week from the fourth month of life until natural death. [4]

Research in tumour models has used yet other schedules. In one experiment on colon carcinogenesis in rats, 1 μg per rat was administered five times a week for six months in one of the experimental groups. [5]

In intranasal studies, quantities expressed in nanograms rather than micrograms were used. An English-language study concerning the rat neocortex reported 30 ng per animal as a single intranasal exposure, whereas an earlier Russian publication from the same research programme reported 2 ng per animal. [6,7] The discrepancy in doses should be preserved rather than artificially standardised, as the publications may concern related but not identical experiments.

These values are best presented as study-specific exposures rather than human-equivalent guidance.

What is the Epithalon Dosage Protocol?

The Epithalon dosing protocol is the full experimental schedule used in a study—including dose, route of administration, frequency, duration of treatment, time of administration, species and evaluated endpoint—rather than merely the number of milligrams per day. Published protocols vary considerably and available clinical evidence has not established a single, universally validated Epitalon protocol for humans.

The word „protocol” is often used on the internet as if it simply means „how much Epitalon to take”. In scientific research, it means much more.

The research protocol may include the amount administered during a single exposure, whether the substance was administered subcutaneously, intranasally, orally, intramuscularly or directly to cultured cells, how frequently exposure occurred, how long the intervention lasted, when measurements were taken and what biological outcome was analysed.

For example, a 2003 ageing study on SHR mice was not limited to the use of „1 μg”. A dose of 1 μg per mouse was administered subcutaneously for five consecutive days each month, starting from the third month of life and continuing until natural death. [1]

However, in the study on lighting in rats, 0.1 μg per rat was administered five times a week, starting from the fourth month of life, and survival and tumour development were observed throughout the animals' lives. [3]

These are fundamentally different protocols, even though subcutaneous administration was used in both cases.

Therefore, a dose value taken out of the context of the entire protocol loses a significant part of its scientific meaning.

What is the difference between Dosage, Frequency and Cycle Length?

The dose, frequency and cycle length describe different elements of the Epithalon research protocol. The dose is the amount administered during a single exposure, the frequency determines how often it is given, and the cycle length denotes the duration of a given treatment period or the number of consecutive days of administration. Published studies have used very diverse combinations of all these parameters.

A good example is the monthly schedule in mice. In the experiment on Swiss-derived SHR mice, the dose was 1 μg per mouse, the frequency within the cycle was once daily for five consecutive days, and the cycle was repeated once a month from the third month of life until natural death. [1]

In another study of HER-2/neu transgenic mice, 1 μg was administered subcutaneously for five consecutive days each month, starting from the second month of life. [8]

In contrast, lighting studies on rats used 0.1 μg per animal five times a week, instead of a short five-day cycle once a month. [3,4]

In the experiment concerning colorectal carcinogenesis, 1 μg was administered five times a week for six months in one of the study groups. [5]

Therefore, the very term „Epitalon protocol” may hide major differences regarding:

• amounts per single administration,
• number of applications per week,
• whether the treatment was intermittent or continuous,
• total duration,
• genre,
• and of the research objective.

For this reason, published animal schemas should not be reduced to a single human „cycle”.

What is the Khavinson Protocol for Epitalon?

There is no single peer-reviewed scientific regimen that can be precisely defined as a universal „Khavinson protocol for Epitalon”. Research associated with Khavinson has used various doses and schedules in mice, rats, monkeys, and laboratory systems, which is why the term is better understood as an informal name for a group of experimental regimens rather than a single standardised clinical protocol.

The term „Khavinson protocol” is widely used in non-scientific discussions, but the published literature does not present a single, uniform regimen applicable across all studies.

Research involving Vladimir Khavinson and his colleagues used various approaches depending on the biological problem being studied.

In mice, one study used 1 μg per mouse for five consecutive days each month. [1] Another used 0.1 μg per animal for five consecutive days each month. [2]

In rats, some ageing studies used 0.1 µg per animal five times a week instead for very long periods. [3,4]

In electrophysiological experiments with intranasal administration, nanogram-level quantities were used as single or short-term research exposures. [6,7]

The literature therefore does not justify reducing Khavinson’s research on Epitalon to a single fixed number of milligrams, a single number of days or a universal, repeated „cycle”.

If a commercial or informal source presents one regimen as the „original Khavinson protocol”, this claim should be verified against the exact original publication from which it supposedly originates.

How Did Injection, Oral, and Nasal Protocols Differ?

Epithalon research using injection, oral and intranasal routes has employed various species, objectives and exposure regimens. Injections dominate aging and oncology studies, oral administration appears primarily in rodent gastrointestinal studies, and intranasal administration has been used chiefly in neurophysiological research and rat pineal stress experiments. These routes are not interchangeable and lack equivalent human validation.

Subcutaneous administration is the most commonly encountered route in older gerontological literature. In studies on mice, regimens such as 0.1 or 1 μg per animal for five consecutive days each month were used, whereas studies on rats frequently utilised 0.1 μg per animal five times a week. [1–4]

Oral administration has been studied mainly in rodents. In one study, Epithalon was administered per os for one month to old Wistar rats, analysing intestinal enzyme activity. The PubMed abstract confirms the route and duration, but does not state the dose, so it should not be made up for this study. [9]

Intranasal administration appears in neurophysiological and stress studies in rats. A 2007 experiment on cortical neurons used a single described dose of 30 ng per animal, whereas a related 2006 Russian publication reports 2 ng. [6,7]

Another study in rats used repeated intranasal administration prior to evaluation of the pineal tissue, but the PubMed abstract does not provide sufficient details regarding the dose to allow a numerical protocol to be presented.

These routes should not be compared as though the same nominal amount leads to the same exposure. Absorption, degradation, tissue distribution and pharmacokinetics differ depending on the route of administration, and robust comparative pharmacokinetic data in humans are unavailable.

What Daily Dosage of Epitalon Was Used in Published Studies?

The published studies used amounts ranging from nanograms in acute intranasal experiments on rats to micrograms per animal in repeated rodent studies. However, the term „daily” can be misleading, as some of the regimens were intermittent, monthly, or restricted to specific treatment days rather than involving continuous daily administration. [1–7]

The examples clearly show this range.

The study on cortical neurones in rats used 30 ng as a single intranasal dose. [6] The related Russian publication reported 2 ng. [7]

In chronic studies on female rats, 0.1 μg per rat was administered on each treatment day, five days a week. [3]

Memory testing in rats also administered 0.1 μg per animal per day, starting from the fourth month of life. [10]

In ageing studies in mice, 0.1 μg or 1 μg per mouse has often been used on each day of treatment, but usually for only five consecutive days each month rather than every day throughout the month. [1,2]

In the experiment regarding colorectal carcinogenesis, 1 μg per rat was administered on each treatment day, five times a week, in a six-month regimen. [5]

One historical publication concerning HER-2/neu constitutes an important exception requiring caution: its PubMed abstract gives 1 mg subcutaneously five times a week, whereas closely related HER-2/neu studies give 1 μg. [11] Because this is a thousandfold discrepancy in very similar experimental literature, the value should be reproduced exactly as published and flagged as requiring verification in the full text, rather than assuming it represents the standard schedule.

What does a 10 mg or 50 mg vial mean?

The 10 mg or 50 mg vial designation indicates the nominal total mass of peptide declared in the container. It does not specify an evidence-based dose, course of treatment, concentration, purity, number of administrations, or appropriate route of administration, and published Epitalon research cannot be translated into a protocol based solely on vial size.

The 10 mg vial nominally contains 10 milligrams of the material labelled as Epitalon, while the 50 mg vial nominally contains 50 milligrams.

Such a statement describes the contents of the packaging, not the study design.

It does not inform:

how much should be given,

how often should it be given,

how should the material be prepared,

does the declared mass refer to pure AEDG or does it also include the salt/counterion share?,

has the declared purity been independently verified,

nor whether the material is sterile or suitable for a specific route of administration.

This distinction is particularly important, as many published animal studies on Epitalon have used quantities at the microgram level rather than the milligram quantities typical of commercial vials. [1–5]

The vial size therefore has no direct equivalent in the dose used in the published study.

When assessing quality, the vial should be analysed separately for identity, purity, analytical documentation, formulation and the intended research context.

Why the Dose Calculator Does Not Replace the Study Protocol

The dosing calculator can perform mathematical operations, but it is unable to determine whether a dose is biologically appropriate, because Epithalon studies vary by species, route of administration, pharmacokinetics, frequency, duration, formulation and endpoint. Simple conversion of a mouse or rat dose based on body weight does not reproduce the exposure or the scientific conditions of the original experiment.

The calculator can answer mathematical questions, such as unit conversion or multiplying quantities by body weight.

Cannot answer pharmacological questions, such as:

is the absorption comparable,

does peptide degradation proceed similarly,

is the same concentration achieved in the tissues,

does the route of administration change bioavailability,

or whether chronic exposure behaves similarly between species.

For example, in a 2003 study on SHR mice, 1 μg per mouse was used, which is approximately 30–40 μg/kg. [1] This does not mean that multiplying a human's body weight by 30–40 μg/kg would replicate the mouse experiment.

The schedule in the mouse was also periodic — five consecutive days a month — and lasted for a significant part of the animal's life. [1]

Similarly, the intranasal dose of 30 ng in the rat was intended for the study of cortical electrical activity for the subsequent 30 minutes, rather than for the study of ageing or clinical efficacy. [6]

Simply converting the numbers therefore removes significant experimental differences.

A calculator can reproduce arithmetic, but not translational pharmacology.

Why Research Doses Should Not Be Presented as Medical Advice

Research dosages should not be presented as medical advice, because most Epitalon regimens originate from animal studies or laboratory experiments, no standard approved human dose has been established for the proposed uses related to anti-ageing, sleep, telomeres or longevity, and translating experimental exposures into self-administration instructions would go beyond the available clinical evidence.

The dose used to test the hypothesis in mice is not automatically a therapeutic dose.

Nasal exposure in the rat used for recording neuronal activity is not automatically a recommendation for nasal dosing.

A long-term scheme in mice designed to study mortality and cancer does not automatically equate to the human longevity cycle.

Published literature on Epitalon also shows considerable variability and sometimes even apparent discrepancies, such as the aforementioned 1 mg and 1 µg values in the HER-2/neu publications. [8,11]

This uncertainty is one of the reasons why experimental quantities should always remain linked to the specific study in which they were applied.

A clinically useful dosing recommendation would require human pharmacokinetic data, dose-response relationships, efficacy, adverse effects, contraindications, interactions, route-dependent safety, and repeated exposure data. These data have not been established for Epitalon at the level required for an approved therapy.

The most appropriate editorial phrasing is therefore:

„The following quantities describe only published experimental protocols and do not constitute recommended human doses or instructions for self-administration.”

Research Dose Summary

The table highlights a key point: published Epitalon research covers many different regimens rather than a single validated dosing protocol.

Epitalon ampoules

Epitalon dosage vials refers to the form of the preparation, which most often occurs as a lyophilised powder. This form is stable and allows for longer storage before the solution is prepared. After dissolution, a solution of a specific concentration is obtained, used according to the chosen protocol.

W in laboratory practice The contents of vials can range from a few to a dozen milligrams. However, the actual dose depends on the volume of solvent used and the method of administration. The lyophilisation process preserves the peptide's structure and allows for precise dosing.

Dissolving Epitalon

The dissolution process of Epitalon is of great importance for the quality of the prepared solution. In laboratory practice, sterile water or bacteriostatic water, which limits microbial growth, is most commonly used.

Dissolving should be done gently, without vigorous shaking, as the structure of peptides is sensitive to mechanical factors. Correct preparation of the solution influences concentration uniformity and result reproducibility, which is particularly important in research.

Dosage of Epitalon in the morning

Epitalon dosage in the morning is analysed in the context of the circadian rhythm and the pineal gland's function. Epitalon shows connections with melatonin regulation, therefore the time of administration may be significant for its effects.

Changes in melatonin and cortisol levels were observed in studies on monkeys and humans, which were dependent on the time of administration. Particularly in older individuals, a normalisation of hormonal rhythms was noted. This suggests that the timing of administration may play a significant role.

Epitalon dosage orally / epitalon orally

Epitalon dosing orally was mainly analysed in rat studies. In one experiment, 100 µg was administered daily for a month. The effect on glucose transport and enzyme activity in the small intestine was observed.

The results indicated an increase in both passive and active transport of nutrients. At the same time, it should be remembered that peptides are susceptible to degradation in the gastrointestinal tract. This may limit their bioavailability in this form.

Epitalon capsules

The capsule form, referred to as epitalon capsule, is less frequently described in studies. However, it appears as an alternative to injections. Its advantage is ease of use.

On the other hand, biological stability and efficacy may be lower due to digestive processes. Therefore, this form remains less well-documented in the context of experimental research.

Transdermal Epitalon

Epitalon transdermal is a field associated with modern peptide delivery methods. In silico studies have analysed the use of carriers, such as dendrimers, which can support transport through the skin.

Although experimental data are still limited, the development of transdermal systems may represent an alternative to injections in the future.

How to use Epitalon?

Epitalon's use depends on the chosen method of administration and the purpose. Various routes have been used in research, including injections, oral administration, and nasal application.

In some experiments, the nasal administration has been shown to lead to rapid effects in the nervous system. This may suggest a central mechanism. Epitalon usage encompassed both short interventions and long-term regimens, demonstrating a broad scope for research applications.

Dosage of the peptide Epitalon

Epitalon peptide dosage indicates the unique property of this compound, which is its activity at very low concentrations. In many cases, the biological effects did not increase with the dose.

Furthermore, situations were observed where lower concentrations yielded stronger effects than higher ones. This non-linear nature of the response suggests regulatory mechanisms rather than a classical dose–response relationship.

Summary

This article is for educational and scientific-information purposes only and does not constitute medical advice, diagnosis, therapeutic guidance or a recommendation for use Epitalon. Epitalon/Epithalon (AEDG; Ala-Glu-Asp-Gly) remains an experimental peptide and is not an FDA- or EMA-approved therapy for the treatment of ageing, telomere shortening, sleep disorders, cognitive decline, cancer, or any other conditions discussed here. A significant portion of the available evidence comes from cell cultures, animal experiments, and other preclinical studies, whereas controlled clinical data involving humans and long-term safety data remain limited. The experimental doses and routes of administration described above are included solely for the purpose of explaining published research and should not be interpreted as instructions for self-administration. Anyone making decisions regarding an experimental peptide or their health status should consult a licensed healthcare professional and verify current regulatory information with the relevant national authority.

References

• Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025 Mar 17;26(6):2691. doi: 10.3390/ijms26062691. PMID: 40141333; PMCID: PMC11943447. https://pmc.ncbi.nlm.nih.gov/articles/PMC11943447/
• [1] Anisimov, V. N., Khavinson, V. K., Popovich, I. G., Zabezhinski, M. A., Alimova, I. N., Rosenfeld, S. V., Zavarzina, N. Y., Semenchenko, A. V., & Yashin, A. I. (2003). Effect of Epitalon on biomarkers of ageing, life span and spontaneous tumour incidence in female Swiss-derived SHR mice. Biogerontology, 4(4), 193–202. https://doi.org/10.1023/A:1025114230714

  [2] Anisimov, V. N., Khavinson, V. K., Mikhalski, A. I., & Yashin, A. I. (2001). Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice. Mechanisms of Ageing and Development, 122(1), 41–68. https://doi.org/10.1016/S0047-6374(00)00184-6

  [3] Vinogradova, I. A., Bukalev, A. V., Zabezhinski, M. A., Semenchenko, A. V., Khavinson, V. K., & Anisimov, V. N. (2007). Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumours in female rats exposed to different illumination regimes. Bulletin of Experimental Biology and Medicine, 144(6), 825–830. https://doi.org/10.1007/s10517-007-0441-z

  [4] Vinogradova, I. A., Bukalev, A. V., Zabezhinski, M. A., Semenchenko, A. V., Khavinson, V. K., & Anisimov, V. N. (2008). Geroprotective effect of Ala-Glu-Asp-Gly peptide in male rats exposed to different illumination regimens. Bulletin of Experimental Biology and Medicine, 145(4), 472–477. https://doi.org/10.1007/s10517-008-0121-7

  [5] Kossoy, G., Ben-Hur, H., Popovich, I., Zabezhinski, M., Anisimov, V., Khavinson, V., & Zusman, I. (2003). Epitalon and colon carcinogenesis in rats: Proliferative activity and apoptosis in colon tumors and mucosa. International Journal of Molecular Medicine, 12(4), 473–477. https://pubmed.ncbi.nlm.nih.gov/12964022/

  [6] Sibarov, D. A., Vol’nova, A. B., Frolov, D. S., & Nozdrachev, A. D. (2007). Effects of intranasal administration of Epitalon on neuron activity in the rat neocortex. Neuroscience and Behavioral Physiology, 37(9), 889–893. https://doi.org/10.1007/s11055-007-0095-3

  [7] Sibarov, D. A., Vol’nova, A. B., Frolov, D. S., & Nosdrachev, A. D. (2006). Intranasal Epitalon infusion modulates neuronal activity in the rat neocortex. Sechenov Physiological Journal of Russia, 92(8), 949–956. https://pubmed.ncbi.nlm.nih.gov/17217245/

  [8] Anisimov, V. N., Khavinson, V. K., Alimova, I. N., Provinciali, M., Mancini, R., & Franceschi, C. (2002). Epithalon inhibits tumour growth and expression of HER-2/neu oncogene in breast tumours in transgenic mice characterised by accelerated ageing. Bulletin of Experimental Biology and Medicine, 133(2), 167–170. https://doi.org/10.1023/A:1015555023692

  [9] Khavinson, V. K., Timofeeva, N. M., Malinin, V. V., Gordova, L. A., & Nikitina, A. A. (2002). Effect of Vilon and Epithalon on activity of enzymes in epithelial and subepithelial layers in small intestine of old rats. Bulletin of Experimental Biology and Medicine, 134(6), 562–564. https://pubmed.ncbi.nlm.nih.gov/12660839/

  [10] Vinogradova, I. A. (2006). Comparative study of the effects of melatonin and Epitalon on protracted memory under shuttle-labyrinth test conditions in rats during ageing. Experimental and Clinical Pharmacology, 69(6), 13–16. https://pubmed.ncbi.nlm.nih.gov/17209456/

  [11] Anisimov, V. N., Khavinson, V. K., Alimova, I. N., Semchenko, A. V., & Yashin, A. I. (2002). Epithalon decelerates ageing and suppresses development of breast adenocarcinomas in transgenic HER-2/neu mice. Bulletin of Experimental Biology and Medicine, 134(2), 187–190. https://doi.org/10.1023/A:1021104819170